Biocon-CHAI Cancer Biosimilars Deal Promises Large Savings
Agreement Covers 30 Countries In Africa And Asia
Biocon Biologics strikes deal with the Clinton Health Access Initiative to provide cost-effective alternatives to pricey reference biologics, beginning with trastuzumab and pegfilgrastim. Savings of over 59% for buyers are expected in some cases.
